Dec 04th 2012 - Edison Investment Research today published a report on Addex Therapeutics entitled "Targeting Deals And Data In 2013". In summary, the report says:
Buoyed by its recent fund-raising and pipeline progress, Addex is entering a critical period in which it hopes to secure a partnership for its lead programme, dipraglurant, for PD-LID and other CNS indications. Encouraging Phase II results for lead partnered drug, JNJ-40411813, being advanced for the treatment of negative symptoms in schizophrenia, raise the prospect of further positive clinical data in 2013 and/or initiation of new clinical studies by J&J. Addex’s internal pipeline should also progress in 2013 with the initiation of Phase I trials for ADX71441.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »